Current market catalysts

8-K filing — Alchemy Investments Acquisition Corp 1 (ALCUF)

Filed: 2026-09-04 AccNo: 0001104659-26-105532 Size: 240 KB Item 5.07: Submission of Matters to a Vote of Security Holders

$100 Invested In Littelfuse 15 Years Ago Would Be Worth This Much Today

Littelfuse (NASDAQ:LFUS) has outperformed the market over the past 15 years by 3.02% on an annualized basis producing an average annual return of 16.42%. Currently, Littelfuse has a market capitalization of $10.64

8-K filing — TOP Financial Group Ltd (TOP)

Filed: 2026-09-04 AccNo: 0001213900-26-097717 Size: 260 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — HARROW, INC. (HROW)

Filed: 2026-09-04 AccNo: 0001493152-26-041569 Size: 207 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

8-K filing — Creative Media & Community Trust Corp (CMCT)

Filed: 2026-09-04 AccNo: 0000908311-26-000103 Size: 189 KB Item 3.02: Unregistered Sales of Equity Securities

Gap 13D/ Amended Filing Shows John J. Fisher Distributes 6.8M Shares; Beneficial Ownership Falls To 13%

- SEC Filing

8-K filing — Stewards, Inc. (SWRD)

Filed: 2026-09-04 AccNo: 0001795851-26-000013 Size: 175 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. Novartis obtained global rights to develop, manufacture and commercialize pelacarsen under a license and collaboration agreement with the company.

8-K filing — Franklin BSP Real Estate Debt, Inc.

Filed: 2026-09-04 AccNo: 0002035428-26-000058 Size: 155 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K filing — SOUNDHOUND AI, INC. (SOUNW)

Filed: 2026-09-04 AccNo: 0001213900-26-097712 Size: 471 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Co-Diagnostics CFO Brian Brown Departs Company; Appoints Daniel Bohrer As Principal Financial Officer, Effective September 2, 2026

On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company’s Chief Financial Officer, determined that Mr. Brown’s last day of employment with the Company would be September 2, 2026

8-K/A filing — CIM GROUP, INC. (CMRF)

Filed: 2026-09-04 AccNo: 0001498547-26-000054 Size: 1 MB Item 9.01: Financial Statements and Exhibits

8-K filing — Stewards, Inc. (SWRD)

Filed: 2026-09-04 AccNo: 0001795851-26-000010 Size: 686 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Cheche Group H1 Adj. EPS $(2.34) Down From $(0.70) YoY, Sales $130.440M Down From $188.265M YoY

Cheche Group (NASDAQ:CCG) reported quarterly losses of $(2.34) per share. This is a 234.29 percent decrease over losses of $(0.70) per share from the same period last year. The company reported $130.440 million in

8-K filing — Weatherford International plc (WFRD)

Filed: 2026-09-04 AccNo: 0001603923-26-000108 Size: 166 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.

8-K filing — AIR T INC (AIRTP)

Filed: 2026-09-04 AccNo: 0000353184-26-000098 Size: 16 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of

8-K filing — Niki BioSolutions, Inc. (NIKI)

Filed: 2026-09-04 AccNo: 0001213900-26-097705 Size: 473 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

8-K filing — Rein Therapeutics, Inc. (RNTX)

Filed: 2026-09-04 AccNo: 0001193125-26-383726 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — CORNING INC /NY (GLW)

Filed: 2026-09-04 AccNo: 0001206774-26-000517 Size: 231 KB Item 7.01: Regulation FD Disclosure

TOP Financial Group Relocates Headquarters To Houston

TOP Financial Group Limited (NASDAQ:TOP, "TOP" or the "Company")), a fast-growing online brokerage firm specializing in local and foreign equities, futures, and options products, today announced the

8-K filing — Arcosa, Inc. (ACA)

Filed: 2026-09-04 AccNo: 0001140361-26-035795 Size: 198 KB Item 5.07: Submission of Matters to a Vote of Security Holders

8-K filing — PANTAGES CAPITAL ACQUISITION Corp (PGACU)

Filed: 2026-09-04 AccNo: 0001213900-26-097703 Size: 252 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

8-K filing — Aperture AC (APURR)

Filed: 2026-09-04 AccNo: 0001213900-26-097700 Size: 378 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

8-K filing — SILGAN HOLDINGS INC (SLGN)

Filed: 2026-09-04 AccNo: 0001628280-26-060742 Size: 139 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

8-K filing — BORGWARNER INC (BWA)

Filed: 2026-09-04 AccNo: 0001104659-26-105519 Size: 241 KB Item 7.01: Regulation FD Disclosure

8-K filing — Aedis Energy Inc. (ALCED)

Filed: 2026-09-04 AccNo: 0001437749-26-029699 Size: 157 KB Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

$100 Invested In Enova International 5 Years Ago Would Be Worth This Much Today

Enova International (NYSE:ENVA) has outperformed the market over the past 5 years by 36.11% on an annualized basis producing an average annual return of 47.38%. Currently, Enova International has a market capitalization

8-K filing — Co-Diagnostics, Inc. (CODX)

Filed: 2026-09-04 AccNo: 0001493152-26-041560 Size: 203 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers